Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Decibel Therapeutics, Inc. (DBTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
10/10/2023 EFFECT Form EFFECT - Notice of Effectiveness:
09/27/2023 SC 13D/A REGENERON PHARMACEUTICALS, INC. reports a 100% stake in Decibel Therapeutics, Inc.
08/25/2023 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements:
08/25/2023 SC TO-T Form SC TO-T - Tender offer statement by Third Party:
08/25/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/18/2023 SC 13D REGENERON PHARMACEUTICALS, INC. reports a 8.3% stake in Decibel Therapeutics, Inc.
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
08/09/2023 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
08/09/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Agreement and Plan of Merger, by and among Decibel Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., and Symphony Acquisition Sub, Inc",
"Form of Contingent Value Right Agreement, by and among Regeneron Pharmaceuticals, Inc., Symphony Acquisition Sub, Inc. and a rights agent mutually agreeable to Regeneron Pharmaceuticals, Inc. and Decibel Therapeutics, Inc",
"Form of Tender and Support Agreement, by and among Regeneron Pharmaceuticals, Inc., Symphony Acquisition Sub, Inc. and certain Stockholders of Decibel Therapeutics, Inc",
"Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel's lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related hearing loss, is in its first clinical trial"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/14/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/06/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BYLAWS OF DECIBEL THERAPEUTICS, INC."
03/21/2023 4 Kapusta Matthew C (Director) has filed a Form 4 on Decibel Therapeutics, Inc.
Txns: Granted 10,000 shares @ $0
Granted 10,000 options to buy @ $3.34, valued at $33.4k
03/21/2023 3 Kapusta Matthew C (Director) has filed a Form 3 on Decibel Therapeutics, Inc.
03/21/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/17/2023 4 Reid Laurence (See Remarks) has filed a Form 4 on Decibel Therapeutics, Inc.
Txns: Granted 195,000 shares @ $0
Granted 72,000 options to buy @ $3.73, valued at $268.6k
03/14/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2023 SC 13G BlackRock Inc. reports a 7.2% stake in DECIBEL THERAPEUTICS INC
01/30/2023 4 Trask Anna (Chief People Officer) has filed a Form 4 on Decibel Therapeutics, Inc.
Txns: Granted 105,000 shares @ $0
Granted 45,000 options to buy @ $3.12, valued at $140.4k
01/30/2023 4 Lee John Jui-Jen (Chief Development Officer) has filed a Form 4 on Decibel Therapeutics, Inc.
Txns: Granted 120,000 shares @ $0
Granted 45,000 options to buy @ $3.12, valued at $140.4k
01/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate presentation dated January 2023",
"Corporate presentation dated January 2023"
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/17/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
10/12/2022 3 MURPHY JAMES B (See Remarks) has filed a Form 3 on Decibel Therapeutics, Inc.
10/12/2022 4 MCLAUGHLIN KEVIN F (Director) has filed a Form 4 on Decibel Therapeutics, Inc.
Txns: Granted 20,000 options to buy @ $2.88, valued at $57.6k
10/12/2022 3 MCLAUGHLIN KEVIN F (Director) has filed a Form 3 on Decibel Therapeutics, Inc.
10/12/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/20/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy